Increased urinary coproporphyrin excretion observed in patients with differently staged Hodgkin's disease treated with chemotherapy

Pinelli, A; Mussini, C; Buratti, M; Parmiggiani-Venezia, Maria; Trivulzio, Silvio

doi:10.1016/j.phrs.2004.09.005

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study of 74 healthy volunteers suggested that the UCP I/(I + III) ratio was dependent on the c.3972C/T polymorphism of ABCC2 , but, by contrast, we found no such association between the ratio and three polymorphisms known to affect MRP2 function in the present study. Impaired porphyrin metabolism has been described in patients with malignancies, leading in most cases to an increase in the urinary excretion of porphyrins, and in particular coproporphyrins . This suggests, retrospectively, that a population of patients with haematological malignancies was perhaps not the most appropriate to test our hypothesis.…”

Section: Discussionmentioning

confidence: 92%

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

Bretagne

Zahr

Gouge

et al. 2014

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims The urinary coproporphyrin I/(I + III) ratio may be a surrogate for MRP2 activity. We conducted a prospective study in patients receiving methotrexate (MTX) to examine the relationship between this ratio and the pharmacokinetics of a MRP2 substrate. Methods Three urine samples were collected from 81 patients for UCP I/(I + III) ratio determination: one before (P1), one at the end of MTX infusion (P2), and one on the day of hospital discharge (P3). Three polymorphisms of ABCC2 were analysed and their relationships with basal UCP I/(I + III) ratio values assessed. All associated drugs were recorded and a drug interaction score (DIS) was assigned. Population pharmacokinetic analysis was conducted to assess whether MTX clearance (MTXCL) was associated with the basal UCP I/(I + III) ratio, its variation during MTX infusion, the DIS or other common covariates. Results The basal UCP I/(I + III) ratio was not associated with ABCC2 polymorphisms and did not differ according to the DIS. Significant changes in the ratio were observed over time, with an increase between P1 and P2 and a decrease at P3 (P < 0.001). No association was found between basal UCP I/(I + III) ratio and MTXCL. The final model indicates that MTXCL was dependent on the change in the ratio between P1 and P3, DIS and creatinine clearance. Conclusion The basal UCP I/(I + III) ratio is not predictive of MTXCL. However, it is sensitive to the presence of MTX, so it is plausible that it reflects a function modified in response to the drug.

show abstract

Section: Discussionmentioning

confidence: 92%

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

Bretagne

Zahr

Gouge

et al. 2014

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…There are few reports of porphyrin metabolism alterations following treatment with chemotherapeutic agents such as cisplatin [5], doxorubicin [39], docetaxel and trastuzumab [2]. As porphyrins are able to form complexes with metallic ions similar to Casiopeina II-gly, the use of this metabolic pathway for biotransformation would not be surprising.…”

Section: Changes In Pathways Related To Metabolismmentioning

confidence: 99%

Identification of Casiopeina II-gly secondary targets through a systems pharmacology approach

Anda-Jáuregui

Espinal-Enríquez

Hur

et al. 2019

Computational Biology and Chemistry

View full text Add to dashboard Cite

show abstract

“…There are few reports of porphyrin metabolism alterations following treatment with chemotherapeutic agents such as cisplatin [5], doxorubicin [39], do-cetaxel and trastuzumab [2]. As porphyrins are able to form complexes with metallic ions similar to Casiopeina II-gly, the use of this metabolic pathway for biotransformation would not be surprising.…”

Section: Resultsmentioning

confidence: 99%

Identification of Casiopeina II-gly secondary targets through a systems pharmacology approach

Anda-Jáuregui

Espinal-Enríquez

Hur

et al. 2018

Preprint

View full text Add to dashboard Cite

Casiopeinas are a group of copper-based compounds designed to be used as less toxic, more efficient chemotherapeutic agents. In this study, we analyzed the in vitro effects of Casiopeina II-gly on the expression of canonical biological pathways. Using microarray data from HeLa cell lines treated with Casiopeina II-gly, we identified biological pathways that are perturbed after treatment. We present a novel approach integrating pathway analysis and network theory: The Pathway Crosstalk Network. We constructed a network with deregulated pathways, featuring links between those pathways that crosstalk with 1 each other. We identified modules grouping deregulated pathways that are functionally related. Through this approach, we were able to identify three features of Casiopeina treatment: a) Perturbation of signaling pathways, related to induction of apoptosis; b) perturbation of metabolic pathways, and c) activation of immune responses. These findings can be useful to drive new experimental exploration on their role in adverse effects and efficacy of Casiopeinas.

show abstract

Increased urinary coproporphyrin excretion observed in patients with differently staged Hodgkin's disease treated with chemotherapy

Cited by 4 publications

References 16 publications

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

Identification of Casiopeina II-gly secondary targets through a systems pharmacology approach

Identification of Casiopeina II-gly secondary targets through a systems pharmacology approach

Contact Info

Product

Resources

About